Filing Flows › 8-K events › Palvella Therapeutics

Palvella Therapeutics: results of operations

Form 8-K filed Nov 5, 2026 · items 2.02, 7.01

FDA decisionsPalvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

What the filing says

FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027 QTORIN™ Rapamycin Could Become the First FDA-Approved Therapy for Microcystic Lymphatic Malformations, a Serious, Rare Lifelong Disease Affecting an Estimated More

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Palvella Therapeutics’s other material 8-Ks

• Oct 28, 2026 — FDA decisions Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PD

Other recent fda decisions

• Biovie Nov 6, 2026
• Acrivon Therapeutics Nov 6, 2026
• Entera Bio Nov 6, 2026
• Precision Biosciences Nov 5, 2026
• Sintx Technologies Nov 5, 2026
• Microbot Medical Nov 5, 2026
• Bioxytran Nov 5, 2026
• ANI Pharmaceuticals Nov 5, 2026
• Teleflex Nov 5, 2026
• Schrodinger Nov 4, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.